Entering text into the input field will update the search result below

Delcath Systems Offers Significant Upside For Risk-Tolerant Investors

Jesse Donovan profile picture
Jesse Donovan


  • Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.
  • There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.
  • Recently released clinical data has provided shareholders with renewed optimism.
  • Financial difficulties must be addressed in the immediate future if Delcath Systems is to succeed.
  • Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.

Delcath Systems (NASDAQ:DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.


This article will begin by discussing Delcath Systems and its proprietary medical products. Next, the diseases that Delcath Systems seeks to treat will be explored. The markets for these diseases will be outlined. The completed and ongoing clinical trials will then be described. The clinical progress in the United States as well as the regulatory and commercial progress in Europe will then be explored. This article will then explore upcoming catalysts for Delcath Systems' and the company's financial position. Finally, potential risks faced by Delcath Systems will be discussed. It will be demonstrated that Delcath Systems presents an asymmetric risk/reward opportunity for investors who are willing to shoulder the risks associated with clinical, regulatory, and financial obstacles.

This article will delve deeply into what has been happening at Delcath Systems for the last several years. Primarily, this thorough analysis is provided because no Seeking Alpha author has published detailed analytical coverage of Delcath Systems since May 2013. One article published on July 7th, 2017 briefly covered Delcath Systems' current financial situation but did not explore other aspects of the company.

Despite the lack of coverage, there have been plenty of significant developments. Therefore, this article will serve to provide investors with a detailed update on the company, its completed and ongoing clinical trials, its progress through regulatory processes, its financial position, and the potential risks faced in the future.

Delcath Systems

Delcath Systems is

This article was written by

Jesse Donovan profile picture
B.A, University of Toronto. Juris Doctor, University of Saskatchewan.I am an individual investor focused on biotech, technology, and natural resources. I have also recently started covering the marijuana industry.I often write about undervalued biotech companies with significant potential to disrupt existing markets. I will increasingly cover the market for recreational and medicinal marijuana which is poised to rapidly expand as legalization takes place in Canada and several American states. I am a graduate of the University of Saskatchewan College of Law and have spent several years researching the interaction between Indigenous rights and natural resource development in North America, Australia, and New Zealand. Much of my writing on Seeking Alpha focuses on the impact of social, legal, and political factors on the North American resource extraction sector.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.